MorphoSys Presents New Antibody Technology arYla
(Thomson Reuters ONE) -
MorphoSys AG /
MorphoSys Presents New Antibody Technology arYla
Processed and transmitted by Thomson Reuters.
The issuer is solely responsible for the content of this announcement.
arYla Opens up New Ways to Optimize Therapeutic and Diagnostic Antibodies
MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX) announced today the
launch of a novel antibody optimization platform called arYla. The Company plans
to use arYla to accelerate antibody optimization, with the goal of generating
superior therapeutic and diagnostic candidates faster and more cost-effectively
than is currently possible. arYla will be used to optimize a range of properties
critical to the successful development of a therapeutic or diagnostic antibody.
The arYla technology results from the combined technology platforms of MorphoSys
and recently acquired Sloning BioTechnology.
"We see many therapeutic and diagnostic antibody programs in our industry in
which shortcomings in the antibody hinder the development of a successful
product," commented Dr. Simon Moroney, Chief Executive Officer of MorphoSys AG.
"arYla gives us a unique and proprietary means of optimizing antibody
properties, which we expect to lead to better products - both therapeutics and
diagnostics - faster than is possible today. We intend to apply the technology
in our own programs and within existing as well as new partnerships, and are
already seeing considerable interest in the pharmaceutical industry."
With the arYla technology, MorphoSys combines more than 15 years of experience
in design and selection of therapeutic antibodies with the unique library
synthesis capabilities acquired with Sloning in October 2010. arYla brings
significant advantages to antibody optimization especially in terms of speed and
flexibility. The new technology enables individualized antibody libraries to be
made with unprecedented speed and precision. arYla will be used to make diverse,
customized sub-libraries based on an existing lead compound, incorporating many
millions of pre-defined variations at precisely determined sites within the
antibody structure. In this way, antibodies optimized for a multitude of
properties, including affinity, specificity, humanness, solubility, stability,
production yield and others, can rapidly be identified.
More information can be found on www.morphosys.com/aryla
+++ Please register now: MorphoSys's R&D Day 2010 +++
London - Thursday, November 25, 2010
New York - Monday, November 29, 2010
www.morphosys.com/rnd-day2010
About MorphoSys:
MorphoSys is an independent biotechnology company that develops novel antibodies
for therapeutic, diagnostic and research applications. The Company's HuCAL
technology is one of the most powerful methods available for generating fully
human antibodies. By successfully applying this and other proprietary
technologies, MorphoSys has become a leader in the field of therapeutic
antibodies, one of the fastest-growing drug classes in human health-care.
Through its alliances with some of the world's leading pharmaceutical companies,
MorphoSys has created a pipeline of more than 60 drug candidates. The Company is
expanding its drug pipeline by adding new partnered programs, and by building a
portfolio of fully-owned therapeutic antibodies. For its proprietary portfolio,
the Company is focused on the areas of oncology and inflammation. Its most
advanced program MOR103, a first-in-class, fully human antibody against GM-CSF,
is currently being tested in a Phase Ib/IIa trial in rheumatoid arthritis
patients. Via its business unit AbD Serotec, MorphoSys is expanding the reach of
its technologies in the diagnostics and research markets. MorphoSys is
headquartered in Munich, Germany and listed on the Frankfurt Stock Exchange
under the symbol "MOR". For further information, visithttp://www.morphosys.com/
HuCAL(®), HuCAL GOLD(®), HuCAL PLATINUM(®), CysDisplay(®) and RapMAT(®) are
registered trademarks of MorphoSys. arYla(TM) is a trademark of MorphoSys.
This communication contains certain forward-looking statements concerning the
MorphoSys group of companies. The forward-looking statements contained herein
represent the judgment of MorphoSys as of the date of this release and involve
risks and uncertainties. Should actual conditions differ from the Company's
assumptions, actual results and actions may differ from those anticipated.
MorphoSys does not intend to update any of these forward-looking statements as
far as the wording of the relevant press release is concerned.
For more information, please contact:
MorphoSys AG
Dr. Claudia Gutjahr-Löser
Head of Corporate Communications & IR
Tel: +49 (0) 89 / 899 27-122
Mario Brkulj
Senior Manager Corporate Communications & IR
Tel: +49 (0) 89 / 899 27-454
Jessica Kulpi
Specialist Corporate Communications & IR
Tel: +49 (0) 89 / 899 27-332
investors(at)morphosys.com
[HUG#1462332]
--- End of Message ---
MorphoSys AG
Lena-Christ-Str. 48 Martinsried / München Germany
WKN: 663200;ISIN: DE0006632003;Index:TecDAX,CDAX,Prime All Share,TECH All Share,HDAX,MIDCAP;
Listed: Freiverkehr in Börse Stuttgart,
Freiverkehr in Hanseatische Wertpapierbörse zu Hamburg,
Freiverkehr in Börse Berlin,
Freiverkehr in Börse Düsseldorf,
Freiverkehr in Bayerische Börse München,
Freiverkehr in Niedersächsische Börse zu Hannover,
Prime Standard in Frankfurter Wertpapierbörse,
Regulierter Markt in Frankfurter Wertpapierbörse;
Press Release:
http://hugin.info/130295/R/1462332/401274.pdf
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: MorphoSys AG via Thomson Reuters ONE
Unternehmensinformation / Kurzprofil:
Datum: 15.11.2010 - 07:30 Uhr
Sprache: Deutsch
News-ID 48751
Anzahl Zeichen: 6973
contact information:
Town:
Martinsried / München
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 210 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"MorphoSys Presents New Antibody Technology arYla"
steht unter der journalistisch-redaktionellen Verantwortung von
MorphoSys AG (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
